for the Alzheimer's Disease Neuroimaging Initiative Group IMPORTANCE Converging evidence indicates that clusterin, a chaperone glycoprotein, influences Alzheimer disease neurodegeneration. However, the precise role of clusterin in Alzheimer disease pathogenesis is still not well understood.
nomewide association studies have identified clusterin gene variants as AD susceptibility loci. 5 Elevated plasma clusterin levels are associated with disease prevalence and severity of AD 6 and with increased amyloid deposition and brain atrophy. 7 Still, experimental findings suggest that clusterin increases both amyloid-β (Aβ) aggregation and clearance, 5 leading to the question of whether elevated clusterin levels are beneficial or harmful.
In humans, structural magnetic resonance imaging (MRI) and CSF biomarkers allow for the indirect assessment of cellular changes underlying AD in vivo. Structural MRI provides measures of brain atrophy, which include loss of dendrites, synapses, 8 and neurons. 9 Low CSF levels of Aβ strongly correlate with intracranial amyloid plaques, and high concentrations of CSF phosphorylated-tau (p-tau) correlate with tauassociated neurofibrillary tangles. 10 Here, we investigated whether interactions between increased CSF clusterin and decreased CSF Aβ and increased CSF clusterin and increased CSF p-tau 181p are associated with increased brain atrophy over time in nondemented older individuals at risk for developing AD. Building on recent evidence that Aβ-associated volume loss occurs in the presence of elevated p-tau, [11] [12] [13] [14] [15] we also examined the additive effect on volume loss of an interaction between increased CSF clusterin and decreased CSF Aβ in the presence of an interaction between increased CSF p-tau at threonine 181 (p-tau 181p ) and decreased CSF Aβ .
Methods
The institutional review boards of all participating institutions approved the procedures of this study, and written informed consent was obtained from all participants or their surrogates.
A total of 313 nondemented older participants from the Alzheimer's Disease Neuroimaging Initiative underwent longitudinal MRI and CSF lumbar puncture. Of these, we restricted analyses to 91 cognitively normal older adults (healthy control [HC] participants) and 150 individuals with amnestic mild cognitive impairment (MCI) who had a quality-assured baseline scan and at least 1 follow-up MRI scan (6 months-3.5 years, 4% with 6-month follow-up, 8% with 12-month follow-up, 11% with 18-month follow-up, 42% with 24-month follow-up, and 35% with 36-month follow-up) (Table; for additional details, see eAppendix 1 and eAppendix 2 in Supplement).
We examined baseline CSF clusterin levels derived from a multiplex-based immunoassay panel based on Luminex immunoassay technology developed by Rules-Based Medicine (MyriadRBM). 16 In brief, the Alzheimer's Disease Neuroimaging Initiative Biomarker Core assessed CSF samples (159 analytes measured by the MyriadRBM) from a total of 327 individuals. These baseline CSF samples had matching aliquots from 1 year, allowing evaluation of test-retest to determine analyte precision. For each analyte, a multistep quality-control procedure was implemented, which included evaluation of CSF signal characteristics (high, medium, and low), assessment for normality of distribution (abnormal values were transformed), and need for imputation (data with missing values and high/low values) (for additional details on CSF qualitycontrol procedures, see the Biomarkers Consortium Data Primer 16 ). We used the quality-controlled values for CSF clusterin in all analyses. Using previously proposed CSF cutoffs, 17 we examined baseline CSF Aβ 1-42 and p-tau 181p levels and classified participants based on low (<192 pg/mL, positive) and high (>192 pg/mL, negative) Aβ 1-42 levels, and high (>23 pg/mL, positive) and low (<23 pg/mL, negative) p-tau 181p levels. As previously described, 17 CSF Aβ 1-42 and p-tau 181p were measured using the multiplex xMAP Luminex platform (Luminex Corp) with Innogenetics (INNOBIA AlzBio3) immunoassay kitbased reagents. We analyzed 977 T1-weighted MRI scans using a modified version of the FreeSurfer software package (http://surfer.nmr .mgh.harvard.edu). These analysis procedures have been applied, validated, and described in detail in a number of publications. 18 The MRI scans were reviewed for quality, automatically corrected for spatial distortion due to gradient nonlinearity, registered, and averaged to improve the signal to noise ratio. The cortical surface was automatically reconstructed and gray matter thickness measurements were obtained at each point across the cortical mantle. Here, we primarily focused middle temporal gyrus, 2 temporal lobe regions that are also affected in AD. 19 The entorhinal cortex and middle temporal gyrus were delineated using an automated, surface-based cortical parcellation atlas. 20 The hippocampus and amygdala were identified using an automated, subcortical segmentation atlas. 21 For the analysis of the longitudinal gray matter volume change, we used Quarc (quantitative anatomical regional change), a method developed from our laboratory. 22, 23 Briefly, each participant's follow-up image was affine aligned to the baseline scan and locally intensity normalized. Using nonlinear registration, a deformation field was then calculated to locally register the images with high fidelity for both large-and small-scale structures including those with low boundary contrast. From the deformation field, a volumechange field (atrophy) can directly be calculated. Using the baseline subcortical and cortical regions of interest, the volumechange field can be sampled at points across the cortical surface or averaged over subcortical regions to give the percentage volume change for those regions of interest ( Figure 1 ). We asked whether statistical interactions between CSF clusterin and CSF Aβ and between CSF clusterin and CSF p-tau 181p are associated with brain atrophy over time ( Figure 2) . Using a linear mixed-effects model, we concurrently examined the main and interactive effects of CSF clusterin, CSF Aβ 1-42, and CSF p-tau 181p on the atrophy rate of the temporal lobe regions (entorhinal cortex, hippocampus, amygdala, and middle temporal gyrus), covarying for age, sex, carrier status for the ε4 allele of apolipoprotein E, group status (MCI vs HC), and disease severity (assessed using Clinical Dementia Rating- To evaluate whether the just-described effects of interest between CSF clusterin, CSF Aβ 1-42 status, and CSF p-tau 181p status were different between the MCI and HC cohorts, we performed additional analyses fitting group status (MCI vs HC) as an interaction with change in time from baseline MRI scan (Δt or time) and the main interactive effects. The main effects of all variables (the 3 CSF analytes and all covariates) were also included in these analyses.
Results
Results from the primary analyses revealed a significant 3-way interaction between CSF clusterin, CSF Aβ 1-42 status, and time (β 5 = −0.032; SE = 0.01; P = .01), indicating that increased CSF clusterin and positive CSF Aβ 1-42 status were associated with an elevated entorhinal cortex atrophy rate. In contrast, the interaction between CSF clusterin, CSF p-tau 181p status, and time was not significant (β 6 = 0.01; SE = 0.01; P = .54). With both of these 3-way interaction terms in the model, only the effect of CSF Aβ 1-42 status by time was significantly associated with the entorhinal atrophy cortex rate (β 3 = 0.04; SE = 0.02; P = .02); the effect of time by CSF clusterin and CSF p-tau 181p status was not associated with the entorhinal cortex atrophy rate. None of the main effects of CSF clusterin, CSF Aβ 1-42 status, and CSF p-tau 181p status were significant. To determine whether these effects differed by group status (MCI vs HC), we performed additional analyses fitting interactions between group status and the main effects of interest (for additional details, see eAppendix 1 and eAppendix 2 in Supplement). These analyses showed a significant interaction between group status, time, CSF clusterin, and CSF Aβ 1-42 status on the entorhinal cortex atrophy rate (β coefficient = −0.031; SE = 0.009; P = .001). Follow-up subgroup analyses revealed that although both the MCI and HC cohorts demonstrated a significant 3-way interaction of time, CSF clusterin, and CSF Aβ 1-42 status on the entorhinal cortex atrophy rate, whereby entorhinal cortex volume loss was significantly associated with CSF clusterin only among CSF Aβ 1-42 -positive individuals, the slopes of change over time were steeper among the MCI cohort than the HC cohort (MCI: β coefficient = −0.076; SE = 0.03; P = .008; HC: β coefficient = −0.047; SE = 0.01; P = .001). The interaction between group status, time, CSF clusterin, and CSF p-tau 181p status was not significant. Similar results were obtained when CSF p-tau 181p and CSF Aβ 1-42 were treated as continuous rather than categorical variables (eAppendix 2 in Supplement).
To determine whether similar associations could be observed in other temporal lobe areas affected later in the disease process, we repeated these analyses using atrophy rates of the hippocampus, amygdala, and middle temporal gyrus.
Figure 2. Diagram of the Primary Hypotheses Evaluated in the Current Study Where the Primary Outcome Was Longitudinal Medial Temporal Lobe Atrophy
Results revealed no significant interactions of CSF clusterin, CSF Aβ 1-42 status, and time on the atrophy rate of the hippocampus (β coefficient = −0.013; SE = 0.01; P = .33), amygdala (β coefficient = −0.015; SE = 0.01; P = .24), and middle temporal gyrus (β coefficient = −0.009; SE = 0.01; P = .39). As observed for the entorhinal cortex atrophy rate, the interaction of CSF clusterin, CSF p-tau 181p status, and time was not significant for the atrophy rate of the hippocampus (β coefficient = 0.004; SE = 0.01; P = .74), amygdala (β coefficient = 0.005; SE = 0.01; P = .74), and middle temporal gyrus (β coefficient = 0.016; SE = 0.01; P = .18).
To determine whether the effect of clusterin on Aβ-associated neurodegeneration is independent from the previously observed effect of p-tau on Aβ-associated neurodegeneration, [11] [12] [13] we included interaction terms with CSF Copyright 2014 American Medical Association. All rights reserved.
Additional interaction analyses with group status demonstrated significant interactions between group status, time, CSF clusterin, and CSF Aβ 1-42 status (β coefficient = −0.020; SE = 0.003; P = .01), as well as between group status, time, CSF p-tau 181p status, and CSF Aβ 1-42 status (β coefficient = −0.008; SE = 0.003; P = .009), on the entorhinal cortex atrophy rate. Subgroup analyses showed that within the MCI cohort, interactions between both CSF clusterin, CSF Aβ 1-42 status, and time (β coefficient = −0.047; SE = 0.02; P = .01), as well as CSF p-tau 181p status, CSF Aβ 1-42 status, and time (β coefficient = −0.014; SE = 0.007; P = .048), on entorhinal cortex atrophy were significant. Within the HC cohort, only the interaction between CSF clusterin, CSF Aβ 1-42 status, and time on entorhinal cortex atrophy was significant (β coefficient = −0.032; SE = 0.01; P = .02); the interaction between CSF p-tau 181p status, CSF Aβ status, and time on entorhinal cortex atrophy was not significant (β coefficient = −0.005; SE = 0.004; P = .23).
Discussion
Here, we showed that in nondemented older individuals, Aβ-associated entorhinal cortex atrophy occurs in the presence of elevated clusterin. We also found that the effect of clusterin on Aβ-associated entorhinal cortex atrophy is not confounded or explained by p-tau. Taken together, this implicates a potentially important role for clusterin in the earliest stages of the Alzheimer neurodegenerative process and suggests independent effects of clusterin and p-tau on Aβ-associated volume loss ( Figure 5 ). Although a number of studies have evaluated the relationship between Aβ, tau, and p-tau on volume loss in the earliest stages of AD, [11] [12] [13] [14] [15] the role of clusterin in modulating this relationship is still unknown. Our findings demonstrated that nondemented older individuals with elevated CSF clusterin and decreased Aβ (ie, increased intracranial Aβ deposition) experience increased volume loss, suggesting that clusterin may accelerate progression from amyloid deposition to neurodegeneration. These results also indicate that a biomarker profile incorporating CSF clusterin, CSF Aβ 1-42 , and CSF p-tau 181p levels may better identify those older individuals who are at an elevated risk for progressing to dementia than any of these biomarkers by themselves. These findings provide novel insights into the preclinical stage of AD. Although prior research suggests that clusterin by itself may not represent a marker of presymptomatic AD, 6 our work indicated that the presence of clusterin may represent a critical link between Aβ deposition and entorhinal cortex degeneration in preclinical AD. Furthermore, in secondary analyses among HC participants, we found a significant interaction on volume loss only between clusterin and Aβ, whereas among individuals with MCI, we noted concurrent interactions of Aβ with both clusterin and p-tau, suggesting that the clusterinrelated effects on Aβ-associated neurodegeneration may precede tau-related effects. Finally, in contrast to p-tau-related atrophy within the later-affected hippocampus or other temporal lobe regions, we found clusterin-associated effects only for the entorhinal cortex, a region selectively affected in the earliest stages of AD. 19 Considered together, these findings indicate that the interaction between clusterin and Aβ may provide an important window into the earliest stages of the Alzheimer neurodegenerative process.
Cellular and molecular evidence suggests that an interaction between clusterin and Aβ potentiates neurotoxicity. Although prior experimental 25 and plasma-based human studies suggested that elevated clusterin levels may represent a nonetiopathologic, neuroprotective response, 6,26 the molecular mechanism by which clusterin affects AD pathology is still not well understood. Recent experimental evidence indicated that knockdown of clusterin protects against Aβ-induced apoptosis, whereas neuronal treatment with Aβ increases intracellular clusterin (and decreases extracellular clusterin), resulting in wnt/Dickkopf-1-induced neurotoxicity. 27 Importantly, this clusterin-dependent, wnt/Dickkopf-1-induced apoptotic effect is specific to Aβ and is not observed with tau or other cytotoxic agents. 27 As a chaperone, clusterin has also been shown to bind with Aβ, thus increasing the rate of fibrillar amyloid deposition and neuritic dystrophy 28 and potentiating Aβ oligomeric neurotoxicity. 29 Consistent with these experimental results, our human findings suggest that clusterin may affect AD neurodegeneration primarily via Aβ-associated mechanisms. A limitation of our study was its observational nature, which precluded conclusions regarding causation. Our results cannot differentiate whether elevated clusterin causes, results from, or is simply correlated with amyloid deposition and entorhinal cortex atrophy. Additionally, our findings require further validation on a larger, independent populationbased cohort.
Conclusions
From a translational perspective, although considerable efforts have focused on Aβ and tau, comparatively little is known about other proteins influencing Alzheimer neurodegeneration. Our findings implicate the involvement of clusterin in the earliest stages of AD. Using experimental models, it will be essential to better delineate the differential mechanistic aspects of intracellular from extracellular clusterin. In humans, it would be helpful to understand whether CSF and plasma clusterin levels correspond to experimentally derived intracellular or extracellular clusterin. It will also be important to determine whether interactions between clusterin and other factors modulate Aβ-associated neurotoxicity. Along with our current findings, the results from these studies could provide valuable insights into whether modifying clusterin levels or blocking clusterin/Aβ interactions are likely to represent viable therapeutic approaches for individuals in the earliest phases of the disease process.
